Anti-Fragile

Solutions 30 - Recovery to 16€

Long
Anti-Fragile Updated   
EURONEXT:S30   SOLUTIONS 30 SE
Since the "big short" from Muddy Waters Capital, Lansdowne Partners, and Gladstone Capital Mgt, Solutions 30 seen its market capitalisation divided by 2, based on an anonymous letter, targeting Mr. Gianpebbi Fortis (Solutions 30 current CEO) in some illegal activities (source AFP December 2020)

As a response, the company opened their door to independent audit and brought up a trial amendment to the AMF (French MArket authority) for market manipulations towards Muddy Waters.

As a matter of fact, this anonymous letter - true or fake - allowed several hedge funds to make a +50% profit in few days (www.quivad.fr/solutions-30) by short-selling the share shortly after the letter release.

As of now, short-sellers still have to unwind their short positions, totalling for up to 4% of total supply.
Moreover, even though the letter tends to turn right, at worst the CEO would face legal issues, but the company would still be operating.

Currently price recovery from 10 to 16€ is in progress, while independent audit to be released circa Q2-2021. At this point, a short-squeeze would be expected, and a price up to 20€ would be on the table.

BUY 10-11€ and wait for independent audit release + hedge funds to unwind their positions (see url www.quivad.fr/solutions-30 to onitor short-sellers)
TARGET 16€ Q1-2020 to 20€ once audit released.
Trade active:
SWEDBANK took opportunity of the -50% dump and reached above 5.2% capital ownership of Solutions 30 as of 21/12/20
Trade active:
12.4€ reach (or +20% since call)
Solutions 30 price appears to be the highest performance on French Market (CAC40 + SBF120) since 2021.

Short-sellers still own more than 3.9% of circulating share supply in short-position.
We still have room to go (15-16€ mid term) until short-selling funds have to unwind their positions.
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.